Tarsus Pharmaceuticals (TARS) Assets Average (2020 - 2026)

Tarsus Pharmaceuticals' Assets Average history runs 7 years deep, the most recent figure standing at $571.6 million for Q1 2026.

• In Q1 2026, Assets Average rose 30.25% year-over-year to $571.6 million; the TTM figure through Mar 2026 stood at $571.6 million (up 30.25% YoY), while the FY2025 annual figure was $469.6 million, up 46.18% from the prior year.
• Assets Average was $571.6 million for Q1 2026 at Tarsus Pharmaceuticals, up from $548.4 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $571.6 million in Q1 2026 to a low of $180.2 million in Q1 2022.
• Historically, Assets Average has averaged $340.3 million across 5 years, with a median of $307.4 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Assets Average decreased 7.87% in 2023, then surged 81.47% in 2024.
• A 5-year view of Assets Average shows it stood at $232.2 million in 2022, then increased by 14.97% to $266.9 million in 2023, then surged by 41.11% to $376.6 million in 2024, then surged by 45.59% to $548.4 million in 2025, then advanced by 4.25% to $571.6 million in 2026.
• The last three Assets Average figures came in at $571.6 million (Q1 2026), $548.4 million (Q4 2025), and $514.8 million (Q3 2025), per Business Quant data.